COVID-19: For information related to COVID-19 (formerly referred to as “novel coronavirus"), visit

VCU Massey Cancer Center


Gynecologic oncology at Massey

VCU Massey Cancer Center’s gynecologic oncology team provides comprehensive care for ovarian, fallopian tube, primary peritoneal, uterine, cervical, vaginal and vulvar cancers as well as gestational trophoblastic disease and many premalignant conditions of the female genital tract. Additionally, we provide care to women at increased genetic risk for these cancers. 

  • Overview

    Comprehensive, advanced care for gynecologic cancers

    VCU Massey Cancer Center is here to help if you or your loved one has been diagnosed with a gynecologic cancer.

    Bindu [View Image]Massey features an award-winning medical team dedicated to caring for patients with cancers of the ovaries, fallopian tubes, primary peritoneum, uterus, cervix, vagina and vulva and with gestational trophoblastic disease. We offer a level of cancer expertise and experience only found at the top 4 percent of cancer centers across the country recognized as a National Cancer Institute-designated Cancer Center. Massey is the only center in the Richmond area, and one of only two in Virginia, designated by the NCI to lead and shape America’s cancer research efforts.

    Massey’s cancer care is provided through VCU Health at VCU Medical Center, which was recognized as the No. 1 hospital in Virginia by U.S. News & World Report (2012, 2013 and 2015). 

    Hallmarks of Massey’s cancer care

    Choose VCU Massey Cancer Center for your gynecologic cancer care because we are:

    Our doctors have unparalleled knowledge and experience in diagnosing and treating all types of gynecologic cancers. As sub-specialists in gynecologic oncology, they are specifically trained in and dedicated to the diagnosis and treatment of cancers of the female reproductive organs.

    Massey offers a full range of treatment options and scope of care, from prevention and diagnosis to treatment, recovery and long-term survivorship. We provide expert care for patients with ovarian, fallopian tube, primary peritoneal, uterine, cervical, vaginal and vulvar cancers and gestational trophoblastic disease. Furthermore, you have access to clinical trials testing new and promising treatments that are only available at National Cancer Institute-designated cancer centers like Massey. Additionally, Massey offers comprehensive support services that help minimize your symptoms and side effects and help you cope with the cognitive, emotional and psychological effects of cancer.

    Massey also offers care for women at increased genetic risk for gynecologic cancers. Furthermore, we provide genetic counseling to women with ovarian or endometrial cancer who may have a family history of cancer or who are concerned about inherited risk. Our Familial Cancer Clinic – the only one of its kind in the Richmond region – offers information, genetic testing and guidance about the inheritable risk of gynecologic cancers so that informed choices can be made and treatment can be personalized. 

    Cancer care generally requires multiple forms of therapy and various specialized doctors. At Massey, our specialists collaborate in interdisciplinary teams to coordinate all aspects and stages of patient care and conveniently provide that care in one location. Massey pioneered the multidisciplinary approach to cancer care in our region. This approach combines the expertise of many doctors and ensures that you will receive the ideal combination and sequence of treatment.

    Recognizing that each patient is unique and each type of cancer is different, Massey provides treatment strategies and care plans tailored and individualized to you.

    Through respectful, attentive and compassionate care, Massey’s cancer care team builds healing relationships with you that help reduce suffering from cancer.

    Care center locations

    VCU Massey Cancer Center – MCV Campus:
    VCU Medical Center, North Hospital                        
    Dalton Oncology Clinic (Ground floor & Basement) & Radiation Oncology Clinic (Basement)
    1300 E. Marshall St.
    (Corner of Marshall Street & College Avenue)
    Richmond, VA 23298
    Phone: (804) 828-9992 Dalton Oncology
    Phone: (804) 828-7232 Radiation Oncology

    Free valet parking is available for outpatient cancer visits at the entrance to North Hospital. Self-parking is available in the Patient and Visitor Parking Deck ($2) at 529 N. 12th St. (at the corner of 12th and Leigh Streets).

    VCU Health at Stony Point – Women’s Health Clinic:
    9000 Stony Point Parkway
    Richmond, VA 23235
    Phone: (804) 828-9165

    Free self-parking is conveniently located at the Stony Point clinics. 

    To make an appointment at either location, please call 804-828-9080.

  • Treatment

    Advanced, comprehensive treatment options

    VCU Massey Cancer Center offers the most effective medical and surgical treatments for gynecologic cancers, including state-of-the-art approaches such as targeted therapies. Additionally, you have the opportunity to enroll in clinical trials testing new and promising therapies that are only available at National Cancer Institute-designated cancer centers like Massey.

    Chemo infusion [View Image]

    Different kinds and combinations of treatment are possible, depending on the type of cancer and the stage at which it is diagnosed. Possible treatments include:

    Surgery – Our gynecologists have unique and specialized training in the surgical management of cancers of the female genital tract. The quality of your surgery impacts the entire course of your cancer treatment. Massey offers a full range of radical and minimally invasive surgical treatments for ovarian, fallopian tube, primary peritoneal, uterine, cervical, vaginal, vulvar cancers and premalignant gynecologic conditions. The type of surgery is individualized to each patient. With traditional “open” surgery, the surgeon uses one large incision to perform a procedure. With laparoscopic surgery, the surgeon makes several small incisions and inserts small tools – including a video camera – to perform the procedure. We also specialize in robotic surgery for staging and treating certain gynecological cancers. The da Vinci robotic platform allows the surgeon to perform complex laparoscopic surgeries with the benefits of a 3D, high definition camera and robotic arms that allow for more precise control and fine movements. For patients who are candidates for minimally invasive surgery, the benefits include shorter hospital stays, faster postoperative recovery and lower rates of postoperative complications.

    Additionally, we follow an Enhanced Recovery After Surgery (ERAS) protocol in our care of patients before, during and after surgery. Through ERAS, our patients are actively involved in their own recovery process. Components of the program are:

    • Pain management. Each patient has a personalized pain management plan designed to limit the use of opioids (narcotics)
    • Early mobility and feeding. We help our patients begin to move and eat as soon after surgery as possible
    • Fluid management. We provide our patients with only as much IV fluid as they need to prevent fluid overload and bloating after surgery

    Following ERAS helps our patients recover faster, leave the hospital sooner and have fewer complications following surgery.

    Chemotherapy – Chemotherapy drugs are usually injected or given by mouth and are used to kill or slow the growth of cancer cells. Some women may have chemotherapy before or after surgery. The chemotherapy experts on our team have years of experience managing gynecologic cancers.

    Clinical trials – Clinical trials are research studies that explore whether a medical strategy, treatment or device is safe and effective, and they also may show which medical approaches work best for certain illnesses or groups of people. Massey offers a wide range of clinical trials for both newly diagnosed and relapsed patients, including some trials that are not found elsewhere. Our trials test new anti-cancer therapies and ways to minimize common cancer-related symptoms. These trials provide access to investigational agents and innovative, new therapies that may help increase the chance for successful treatment.

    Hormone therapy – Hormone therapy is a cancer treatment that slows or stops the growth of cancer that uses hormones to grow. Hormone therapy may be used for women who cannot have surgery or radiation therapy, or it may be used in combination with other types of treatment. Hormone therapy may be given orally as a pill, by injection or through the surgical removal of the ovaries, which produce hormones.

    Radiation therapy – Radiation therapy uses high-energy x-rays to kill cancer cells and stop them from spreading. Radiation therapy is used in the treatment of many gynecologic cancers including cervical, endometrial, vulvar, vaginal and ovarian.  It can be delivered after surgery to destroy any cancer cells remaining in the area, before surgery to shrink the tumor or in place of surgery, and is often combined with chemotherapy. The most common type of radiation treatment is called external beam radiation therapy, which is radiation given from a machine outside the body. The other type is internal radiation treatment known as brachytherapy, which is delivered by a source that is placed inside of the body. Our radiation oncologists are experts in both types of radiotherapy and customize the treatments to each of our patients.

    Targeted therapies / precision medicine – Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules (“molecular targets”) that are involved in the growth, progression and spread of cancer. Targeted therapies are the foundation of precision medicine, a form of medicine that uses information about a person’s genes and proteins to prevent, diagnose and treat disease. An example of a targeted therapy for gynecologic cancers recently approved by the FDA is olaparib. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair, and olaparib is approved for germline BRCA mutated advanced ovarian cancer. 

  • Specialists

    Leading experts in gynecologic cancers

    Your medical team at VCU Massey Cancer Center has a depth and breadth of expertise and experience that is specialized in the diagnosis and treatment of gynecologic malignancies. These specialists collaborate in a multidisciplinary team, which offers you the advantage of one-stop consultations and highly coordinated care. Many of our doctors are also researchers who continually investigate new and better treatment options and are exploring ways to improve the patient care experience. And as Massey is part of a university medical center, our doctors are also professors, educating and training oncologists and other health care professionals. The treatment, study and teaching of gynecologic cancers position our doctors as the leading experts in the field.


    Select from the list below to learn more about your care team and their education, training and specific areas of clinical expertise.

    Gynecologic oncology

    Image of Leslie Randall, M.D., MASLeslie Randall, M.D., MAS [View Image]
    Image of Stephanie Sullivan, M.D.Stephanie Sullivan, M.D. [View Image]

    Massey’s gynecologic oncologists are faculty in the Division of Gynecologic Oncology within the Department of Obstetrics and Gynecology of the VCU School of Medicine at VCU Health.

    Your gynecologic oncology team also includes:

    • Sara Baffuto, MSN, nurse practitioner
    • Dakota Clemmons, BSN, RN, nurse navigator
    • Marcie Templeton, BS, patient coordinator

    Medical oncology

    Image of Sarah Gordon, D.O.Sarah Gordon, D.O. [View Image]

    Massey's medical oncologists are faculty in the Division of Hematology, Oncology and Palliative Care within the Department of Internal Medicine of the VCU School of Medicine at VCU Health.

    Radiation oncology

    Image of Emma Fields, M.D.Emma Fields, M.D. [View Image]

    Fields is on faculty in the Department of Radiation Oncology of the VCU School of Medicine at VCU Health.


    Image of Sadia Sayeed, M.D.Sadia Sayeed, M.D. [View Image]

    Massey’s pathologists are faculty in the Department of Pathology of the VCU School of Medicine at VCU Health.


    Image of Ann Fulcher, M.D.Ann Fulcher, M.D. [View Image]

    Fulcher is the chair of the Department of Radiology of the VCU School of Medicine at VCU Health.

    Genetic counseling

    Image of John Quilin, Ph.D., CGCJohn Quilin, Ph.D., CGC [View Image]
    Image of Heather Creswick, M.S., CGCHeather Creswick, M.S., CGC [View Image]

    Massey's genetic counselors operate Massey's Familial Cancer Clinic and are faculty in the Department of Human and Molecular Genetics of the VCU School of Medicine at VCU Health.


    Additional medical team members

    Others who may be part of your health care team include attending and resident physicians, fellows, palliative care specialists, nurses, genetic counselors, physical therapists, occupational therapists, social workers, psychologists, chaplains, nutritionists, care partners, clerks and other specialists as needed.

    To connect with our gynecologic oncology team, please call us at 804-828-9080.

  • Research

    One of the biggest benefits to receiving care at VCU Massey Cancer Center is having access to new treatments or technologies being tested in clinical trials before they are approved for widespread use. As a clinical trial participant, you are helping to shape the care of future patients while still receiving the best cancer care possible. Clinical trials never use a placebo when a current treatment option exists, so participants receive the best known treatment for their disease or one that is potentially better.

    Below are some of the exciting clinical trials options available at Massey for patients with gynecologic cancers. To learn more about any of these trials, please contact Sonya Washington, R.N., clinical research nurse coordinator, at (804) 628-2582 or email

    Visit to view our entire menu of clinical trials.

    GOG-3030: A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

    • This is a Phase 3 clinical trial testing an immunotherapy drug called atezolizumab for the treatment of metastatic or recurrent cervical cancer. Atezolizumab is an immunotherapy drug that targets the PD-L1 protein to help the immune system recognize and attack cancer cells. It has been approved to treat aggressive lung, breast and liver cancers, but this is the first time it’s being tested for cervical cancer.
    • Participants in the clinical trial will be randomized into two groups, one receiving the experimental therapy and the other receiving the current standard of care. Both groups will be closely monitored during and after treatment for side effects and treatment responses.


    AK104-201-AU: A Phase 2, multicenter, single-arm, open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer

    • This is a Phase 2 clinical trial testing a new, experimental immunotherapy drug known as AK104 for patients with recurrent or metastatic cervical cancer. AK104 is a promising immunotherapy drug that has already shown responses in a small number of women. It targets two proteins, PD-1 and CTLA-4, to enhance the immune system’s ability to destroy cancer


    NRG-GY009: A Phase 2 / 3 Study Comparing Three Drug Regimens Using Liposomal Doxorubicin, Bevacizumab, and/or Atezolizumab Immunotherapy to Treat Recurrent or Persistent Ovarian Cancer

    • This study evaluates the addition of the immunotherapy drug atezolizumab to the current standard therapy of liposomal doxorubicin and bevacizumab to treat ovarian cancer resistant to platinum-based chemotherapy. Atezolizumab targets a protein that helps the immune system recognize and attack cancer cells. It is already approved for the treatment of bladder and lung cancer.


    GOG-3048: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 in Patients with Solid Tumors Likely to Express NaPi2b (Ovarian & NSCLC)

    • This Phase 1b clinical trial will establish the recommended tolerated dose of XMT-1536 for women with platinum-resistant, high-grade serous ovarian cancer and non-small cell lung cancer. XMT-1536 is an experimental drug targeting NaPi2b, a tumor-associated antigen (TAA) that is expressed on a variety of cancer cells.
    • Participants will receive XMT-1536 as an infusion once every four weeks. After the first cycle, participants may continue to receive XMT-1536 until disease progression provided the drug is well-tolerated and they continue to derive clinical benefit.

    NRG-GY021: A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

    • This Phase 2 clinical trial will test if the addition of tremelimumab improves the standard treatment for platinum-sensitive recurrent ovarian cancer. The current standard treatment is olaparib, a medication known as a PARP inhibitor. Tremelimumab is an investigational immunotherapy drug that blocks the CTLA4 protein to potentially enhance the immune system’s ability to fight cancer. This study will determine if adding tremelimumab helps prevent cancer growth and spread.
    • This study is for women with ovarian, fallopian tube or peritoneal cancer that has not come back within six months of receiving platinum-based treatments. Patients will be randomly assigned to receive olaparib alone or olaparib plus tremelimumab.

    NRG-GY020: A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer

    • This Phase 3 trial compares whether the addition of pembrolizumab to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer coming back (recurrence) in patients with newly diagnosed stage I-II endometrial cancer.
    • Pembrolizumab is an immunotherapy that helps the body recognize and attack cancer cells. The addition of pembrolizumab to radiation treatment may be more effective than radiation treatment alone in reducing cancer recurrence.

    NRG-GY005: A Randomized Phase 2/3 Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

    • This randomized Phase 2 / 3 trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving chemotherapy with drugs that contain platinum or continued to grow while being treated with platinum-based chemotherapy drugs.
    • Cediranib maleate and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cediranib maleate and olaparib together may cause more damage to cancer cells when compared to either drug alone or standard chemotherapy.


    • This trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for women with BRCA1 mutations. Women with BRCA1 mutations may opt to undergo the surgical removal of both their fallopian tubes and ovaries (bilateral salpingo-oophorectomy) in order to reduce their risk of cancer. However, many women may wish to only remove their fallopian tubes (bilateral salpingectomy) initially and remove their ovaries at a later date. This study may help doctors determine the comparative cancer risk reduction of both surgical approaches.


  • Resources

    Support services

    At VCU Massey Cancer Center, we believe that treating the whole person, not just the disease, is the best way to care for patients and family members coping with cancer. We take a holistic approach to address not just your medical and physical needs, but also your psychological, emotional and social needs. We offer comprehensive cancer support services to care for you throughout your cancer journey that range from helping minimize symptoms and side effects to helping evaluate and cope with the emotional and psychological effects of cancer. These services include:

    [View Image]

    Communication assistance, including language translation services, text and amplified telephones for the hearing impaired, sign language and cued speech interpreters

    Integrative health resources, including acupressure, art therapy, music therapy, pet therapy and tobacco cessation counseling. Complementary therapies are not substitutes for medical care but are used together with medical treatments to help patients alleviate stress and anxiety, reduce pain, manage symptoms and promote a feeling of well-being.

    Financial assistance for qualifying patients in need

    Genetic counseling by board-certified genetic counselors in Richmond’s only Familial Cancer Clinic

    Healing garden

    Legal assistance for qualifying patients in need

    Lodging for qualifying patients in need

    • Nutritionists

    Palliative care by an international award-winning team for the management of pain and symptoms, including an outpatient Supportive Care Clinic

    Patient education, including libraries and health programming geared to cancer patients and their caregivers

    Pharmacy services, including in-hospital oncology pharmacies

    Psychological counseling - ask your nurse for more information

    Rehabilitation by one of the nation’s longest-running cancer rehabilitation programs with physical, occupational and speech therapy especially geared for cancer patients

    • Spiritual counseling

    Social work for patients in need

    Support groups

    Transportation assistance for qualifying patients in need – ask your social worker for more information

    Wig salons that provide free hats, scarves and wigs as well as private head-wear consultation services

    Learn more about our patient resources and integrative medicine

Request an appointment

or call: 804-828-9080

[View Image] Why consider a clinical trial

Treatments in clinical trials may be more effective or have fewer side effects than the treatments that are currently available. Learn more about clinical trials »

Learn more:

Related news:

View graphic versionView graphic version